These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25541135)

  • 1. Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
    Lymperopoulos A; Sturchler E; Bathgate-Siryk A; Dabul S; Garcia D; Walklett K; Rengo G; McDonald P; Koch WJ
    J Am Coll Cardiol; 2014 Dec; 64(25):2805-6. PubMed ID: 25541135
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
    Swedberg K; McMurray JJ
    Eur Heart J; 2004 Mar; 25(5):357-8. PubMed ID: 15033244
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
    [No Abstract]   [Full Text] [Related]  

  • 5. Valsartan, captopril, or both in myocardial infarction.
    McAnulty JH
    N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
    [No Abstract]   [Full Text] [Related]  

  • 6. HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
    McMurray JJ; Swedberg K
    Eur J Heart Fail; 2010 Feb; 12(2):99-103. PubMed ID: 20083618
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin receptor blockers and myocardial infarction.
    Verma S; Strauss M
    BMJ; 2004 Nov; 329(7477):1248-9. PubMed ID: 15564232
    [No Abstract]   [Full Text] [Related]  

  • 8. [Angiotensin receptor blockers in chronic heart failure].
    Umemoto S; Kawahara S; Hashimoto R; Matsuzaki M
    Nihon Rinsho; 2003 Sep; 61(9):1683-9. PubMed ID: 14515740
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldosterone levels after angiotensin receptor blocker treatment.
    Folkeringa RJ; Pinto YM; Crijns HJ
    Circulation; 2004 Apr; 109(14):e182; author reply e182. PubMed ID: 15078811
    [No Abstract]   [Full Text] [Related]  

  • 10. [VALUE].
    Okura T; Higaki J
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():419-24. PubMed ID: 16981573
    [No Abstract]   [Full Text] [Related]  

  • 11. [Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].
    MMW Fortschr Med; 2004 Aug; 146(33-34):52. PubMed ID: 15526635
    [No Abstract]   [Full Text] [Related]  

  • 12. [Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
    Zidek W
    MMW Fortschr Med; 2004 Jul; 146(27-28):41. PubMed ID: 15526662
    [No Abstract]   [Full Text] [Related]  

  • 13. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effect of angiotensin II type 1 receptor blocker valsartan in rats with portal hypertensive gastropathy].
    Huo LJ; Huang HF; Yang BY
    Zhonghua Gan Zang Bing Za Zhi; 2006 Aug; 14(8):611-3. PubMed ID: 16938177
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
    MMW Fortschr Med; 2006 Feb; 148(5):48-9. PubMed ID: 16518941
    [No Abstract]   [Full Text] [Related]  

  • 17. VALIANT trial results support use of valsartan in acute myocardial infarction.
    Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT.
    Voors AA; van Veldhuisen DJ
    Int J Cardiol; 2004 Dec; 97(3):345-8. PubMed ID: 15561317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lowering blood pressure substantially--and the diabetes risk as well?].
    MMW Fortschr Med; 2006 Jul; 148(29-30):48-9. PubMed ID: 16910410
    [No Abstract]   [Full Text] [Related]  

  • 20. [On angiotensin II receptor distribution after myocardial infarction in dogs].
    Qu XF; Li JJ; Xi Y; Shen JX; Xiu CH; Yue L; Wang GZ; Huang YL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):358-62. PubMed ID: 19791474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.